Is there a Bearish outlook for Exact Sciences Corporation (NASDAQ:EXAS) this week?

Exact Sciences Corporation (NASDAQ:EXAS) Logo
Investors sentiment decreased to 1.26 in 2019 Q2. Its down 0.03, from 1.29 in 2019Q1. It dived, as 31 investors sold Exact Sciences Corporation shares while 113 reduced holdings. 76 funds opened positions while 106 raised stakes. 108.62 million shares or 14.41% less from 126.90 million shares in 2019Q1 were reported.
Tobam accumulated 592 shares or 0% of the stock. Glenmede Tru Na invested in 0% or 197 shares. Axa accumulated 56,709 shares. 52,900 were reported by Rh Dinel Invest Counsel. Morgan Stanley holds 0.03% in Exact Sciences Corporation (NASDAQ:EXAS) or 816,031 shares. Brown Brothers Harriman And holds 0% or 704 shares in its portfolio. Parametric Port Limited Liability Company holds 159,684 shares or 0.02% of its portfolio. Lazard Asset Mgmt Lc invested 0% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Wisconsin Capital Mgmt invested in 29,425 shares. Riverhead Ltd Liability Corp holds 34,761 shares. Dnb Asset Management As holds 12,748 shares. Baystate Wealth Ltd Liability Co holds 0% or 60 shares. Caxton Assoc Lp reported 2,281 shares. Natixis Advisors L P accumulated 18,523 shares. Strs Ohio holds 0.03% or 66,584 shares.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 3 analysts covering EXACT Sciences (NASDAQ:EXAS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. EXACT Sciences has $14300 highest and $11000 lowest target. $124.33’s average target is 16.51% above currents $106.71 stock price. EXACT Sciences had 6 analyst reports since March 15, 2019 according to SRatingsIntel. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Wednesday, May 1 by Canaccord Genuity. The firm has “Buy” rating by Goldman Sachs given on Friday, April 12. The rating was maintained by UBS on Wednesday, May 1 with “Buy”. UBS maintained Exact Sciences Corporation (NASDAQ:EXAS) on Thursday, August 1 with “Buy” rating. UBS maintained the shares of EXAS in report on Tuesday, April 16 with “Buy” rating. Below is a list of Exact Sciences Corporation (NASDAQ:EXAS) latest ratings and price target changes.

01/08/2019 Broker: UBS Rating: Buy Old Target: $120.0000 New Target: $143.0000 Maintain
01/05/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $115.0000 New Target: $120.0000 Maintain
01/05/2019 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $100.0000 New Target: $110.0000 Maintain
16/04/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $109 New Target: $115 Maintain
12/04/2019 Broker: Goldman Sachs Old Rating: Buy New Rating: Buy New Target: $120 Maintain
15/03/2019 Broker: BidaskScore Rating: Buy Upgrade

The stock decreased 1.82% or $1.98 during the last trading session, reaching $106.71. About 1.03M shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 100.54% since September 13, 2018 and is uptrending. It has outperformed by 100.54% the S&P500.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $13.77 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

More notable recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: which released: “Interesting EXAS Put And Call Options For January 2019 – Nasdaq” on November 29, 2018, also with their article: “Notable ETF Outflow Detected – VB, EXAS, ATO, BURL – Nasdaq” published on June 12, 2019, published: “EXAS Crosses Above Average Analyst Target – Nasdaq” on May 03, 2019. More interesting news about Exact Sciences Corporation (NASDAQ:EXAS) were released by: and their article: “EXACT Sciences Breaks Below 200-Day Moving Average – Notable for EXAS – Nasdaq” published on December 20, 2018 as well as‘s news article titled: “Earnings Preview: Exact Sciences (EXAS) Q1 Earnings Expected to Decline – Nasdaq” with publication date: April 23, 2019.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.